'Reprogrammed' treatment-resistant lymphomas respond to cancer drugs

A phase I clinical trial showed diffuse, large B-cell lymphomas resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discover y, a journal of the American Association for Cancer Research.

http://www.eurekalert.org/pub_releases/2013-08/aafc-tl081413.php